SXSW 2022
Paving New Paths with Personalized Medicine
Description:
It’s time to make personalized medicine a priority. With people focused more on their health than ever and the cost of managing illnesses skyrocketing—now is prime time for AI-powered prevention of chronic diseases. The personalized medicine market is expected to grow to more than $278B by 2030, increasing the technology’s accessibility for the general public. In this session, a panel of senior healthcare experts and visionary investors—from Freenome, RAPT Therapeutics, VIA Global Health, and Mighty Capital—will lay out the transformative effect personalized medicine will have on patient care, disease prevention, and health outcomes.
Related Media
Takeaways
- Hear how the Mobile Era influenced personalized medicine and how the AI developed for mobile is now fueling the data that’s driving healthtech.
- Hear real-world examples of how personalized medicine startups are innovating healthcare.
- Discover what’s on the horizon for personalized medicine, and what predictions the panelists see in AI-powered prevention.
Speakers
- SC Moatti, Managing Partner, Mighty Capital
- Renee Niemi, Member Board of Directors, VIA Global Health
- Brian Wong, CEO, RAPT Therapeutics
- Asia Chang, VP Commercial Strategy & Operations, Freenome
Organizer
Justine Pallas, Director, credPR
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments